Thymidylate synthase expression and activity: Relation to S-phase parameters and 5-fluorouracil sensitivity

British Journal of Cancer

Volumn 78, Issue 1, 1998, Pages 62-68

  Mirjolet, J F ^a   Barberi Heyob, M ^a   Merlin, J L ^a   Marchal, S ^a   Etienne, M C ^b   Milano, G ^b   Bey, P ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

5 fluorouracil; Cancer cell line; Labelling index; S phase; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; PROTEIN P53; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE PARAMETERS; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031832182     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.443     Document Type: Article

References (33)

1. Aguilar Santelises M, Rottenberg ME, Lewin N, Mellstedt H and Jondal M (1996) Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 69: 114-119
2. Ali Imam AM, Crossley PH, Jackman AL and Little PFR (1987) Analysis of thymidylate synthase gene amplification and mRNA levels in the cell cycle. J Biol Chem 262: 7368-7373
3. Barberi Heyob M, Griffon G, Merlin JL and Weber B (1993) Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole. Cancer Chemother Pharmacol 33: 163-170
4. Barberi Heyob M, Weber B, Merlin JL, Dittrich C, de Bruijn EA, Luporsi E and Guillemin F (1995) Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities. Cancer Chemother Pharmacol 37: 110-116
5. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano G (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil (see comments). Eur J Cancer 30a: 1517-1522
6. Begg AC, Hofland I, Van Glabekke M, Bartelink JC and Horiot JC (1992) Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin Radiat Oncol 2: 22-25
7. Cadman E and Heimer R (1986) Levels of thymidylate synthase during normal culture growth of L1210 cells. Cancer Res 46: 1195-1198
8. Chou TC and Talalay P (1987) Application of the median-effect principle for the assessment of low dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In New Avenues in Developmental Cancer Chemotherapy, Vol. 37. Harrap KR and Connors TA (eds), pp. 37-64. Academic Press: New York.
9. Chu E and Allegra CJ (1996) The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul 36: 143-163
10. Chu E, Lai GM, Zinn S and Allegra CJ (1990) Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol 38: 410-417
11. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S and Allegra CJ (1991a) Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 88: 8977-8981
12. Chu E, Drake JC, Koeller DM, Zinn S, Jamis Dow CA, Yeh GC and Allegra CJ (1991b) Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136-143
13. Conrad AH (1971) Thymidylate synthase activity in cultured mammalian cells. J Biol Chem 39: 1318-1323
14. Evans RM, Laskin JD and Hakala MT (1980) Assesment of growth-limiting events caused by 5-fluorouracil in mouse cells and human cells. Cancer Res 40: 4113-4122
15. Fety R, Rolland F, Campion L, Perrocheau G, Merlin JL, Barberi-Heyob M, Conroy T, Hardouin A, Riviere A and Milano G (1997) A multicentric randomized trial of 5-fluorouracil (FU) dose adaptation (DA) based on pharmacokinetics (PK); clinical and economic impacts. Proc Am Soc Clin Oncol 16: 225a
16. Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903-909
17. 2-microglobulin gene: primary structure and definition of the transcriptional unit. J Immunol 139: 3132-3138
18. Harris BE, Song R, Soong SJ and Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation if enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201
19. Jenh CH, Rao LG and Johnson LF (1985) Regulation of thymidylate synthase enzyme synthesis in 5-fluorodeoxyuridine-resistant mouse fibroblasts during the transition from the resting to growing state. J Cell Physiol 122: 149-154
20. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T and Altman S (1987) Role in translation of the triple tandemly repeated sequence in the 5′-untranslated region of the human thymidylate synthase mRNA. Nucleic Acids Res 15: 1259-1270
21. Marchal S, Marchal C, Parache RM, Benjaafar N, Odda M, Leclerc A, Merlin JL, Gueddarri BE and Bey P (1997) Combined flow cytometry and immunohistochemistry analyses for the assessment of nasopharyngeal carcinoma cell kinetics by in vivo BrdUrd infusion. Cytometry 29: 165-172
22. Matherly LH, Schuetz JD, Westin E and Goldman ID (1989) A method for the synchronisation of cultured cells with aphidicolin: application of L1210 cells and the study of the cell cycle regulation of thymidylate synthase and dihydrofolate reductase. Anal Biochem 182: 338-345
23. Mirjolet JF, Barberi-Heyob M, Marchal S, Colosetti P and Merlin JL (1997) In human cancer cell lines, thymidylate synthase expression and activity are principally associated with cells cycle variations. Proc Am Assoc Cancer Res 38: 476
24. Pestalozzi BC, McGinn CJ, Kinsella TJ, Drake JC, Glennon MC, Allegra CJ and Johnston PG (1995) Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 71: 1151-1157
25. Peters GJ and Van Groeningen CJ (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2: 469-480
26. Peters GJ, Van Der Wilt CL and Van Groeningen CJ (1994) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 30A: 1408-1411
27. Plucinski TM, Fager RS and Reddy GP (1990) Allosteric interaction of components of the replitase complex is responsible for enzyme cross-inhibition. Mol Pharmacol 38: 114-120
28. Riccardi A, Danova M, Wilson G, Ucci G, Dörmer P, Mazzini G, Brugnatelli S, Girino M, McNally NJ and Ascari E (1988) Cell kinetics in human malignancies studies with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res 48: 6238-6245
29. Schimke RT (1984) Gene amplification, drug resistance, and cancer. Cancer Res 44: 1735-1742
30. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Gooke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85
31. Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP and Goldman ID (1982) Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high-performance liquid chromatography. J Biol Chem 4: 2858-2864
32. Storms RK, Ord RW, Greenwood MT, Mirdamadi B, Chu FK and Belfort M (1984) Cell cycle dependent expression of thymidylate synthase in Saccharomyces cerevisiae. Mol Cell Biol 4: 2858-2864
33. Takeishi K, Kaneda S, Ayusawa D, Shimizu K, Gotoh O and Seno T (1985) Nucleotide sequence of a functional cDNA for human thymidylate synthase. Nucleic Acids Res 13: 2035-2043